ALPHARETTA, Ga., Feb. 14, 2016 /PRNewswire/ -- Ennaid
Therapeutics, located in Alpharetta,
GA is developing therapeutic cures to help the millions of
people worldwide when infected with the mosquito-borne
disease, Zika Virus, now named a global public health emergency by
the World Health Organization and the CDC. The global health
community is urging caution and care in response to Zika's
explosive spread and is calling for rapidly stepped up efforts
by researchers to find therapeutics and vaccines for
those who contract it.
For years, Ennaid Therapeutics has been committed to developing
cures for mosquito-borne diseases, including Dengue,
Chikungunya and Zika viruses – and is now advancing its work on
Zika to address the urgent global need.
Zika Virus
Zika is linked to microcephalic birth defects and possible eye
damage in babies. The virus, which is transmitted by Aedes
species mosquito, has infected 1 million Brazilians and 50+ people
in the United States. An estimated
4 million infections are expected in the Americas in 2016. Zika's
risk to pregnant women is a top priority, according to the
CDC.
"Zika virus, which is now our focus, has been in our
ten-product pipeline for years, and we will continue developing
cures for the growing numbers of Dengue, West Nile and Chikungunya
sufferers, among other mosquito-borne diseases," says
Darnisha Harrison, Ennaid
Therapeutics' CEO.
Please see link below of Discovery Channel's
"Innovations with Ed Begley,
Jr.", in which Ennaid Therapeutics will be
featured:
http://www.prweb.com/releases/2015/10/prweb13028491.htm.
Ennaid Therapeutics' Science
- Our peptide fusion inhibitors show significant inhibition
against many Flaviviridae family of viruses, such as Dengue and
possibly Zika; both carried by the Aedes species mosquito,
and both of the flavivirus genus
- Our peptide's stem mimic the stem of many Flaviviridae viruses,
thus inhibiting viral infections
- Zika stem is a very close match to our peptide's stem and
feasibility studies are underway.
- Already planned development studies will determine our
peptide's inhibition against Zika virus in vivo and safety in
pregnancy
- Our fast-track development strategy will then allow Ennaid
Therapeutics to immediately begin clinical trials, as
funding is secured
- Currently there are safe and effective commercialized peptide
fusion inhibitors, such as Enfuvirtide, brand name Fuzeon
Ennaid Therapeutics
Founded in 2012, Ennaid Therapeutics is developing a
proprietary platform technology of flavivirus fusion inhibitors
that show significant inhibition against flavivirus infectivity,
such as Dengue, et al. Their rapid development plan has the
potential to safely and quickly bring a Zika virus therapeutic
cure to market in record time.
Darnisha Harrison, Ennaid
Therapeutics CEO
Formerly a Microbiologist and Chemist, Ms. Harrison is
a nationally recognized pharmaceutical entrepreneur by
Newsweek magazine. With 22 years' experience in the life
sciences, she is a member of the American Association for the
Advancement of Science and the New York Academy of Sciences. She
received a Bachelor of Science in Microbiology and a Minor in
Chemistry from LSU.
For interviews, investment or more information contact:
Gigi Gilbert, Public Relations,
Phone: +404-309-7034, Email: Gigi@ennaidthera.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ennaid-therapeutics-prioritizes-zika-virus-rapid-drug-development-in-wake-of-crisis-300219899.html
SOURCE Ennaid Therapeutics